Trinity Biotech
TRIB
28 hedge funds and large institutions have $12.9M invested in Trinity Biotech in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 9 closing their positions.
0.01% less ownership
Funds ownership: 0.08% → 0.07% (-0.01%)
18% less funds holding
Funds holding: 34 → 28 (-6)
36% less capital invested
Capital invested by funds: $20.2M → $12.9M (-$7.34M)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $29K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$959K |
| 2 |
FM
Fondren Management
Houston,
Texas
|
+$591K |
| 3 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$94.9K |
| 4 |
CCM
Covington Capital Management
Los Angeles,
California
|
+$5.73K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LAM
Lapides Asset Management
Greenwich,
Connecticut
|
-$1.08M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$835K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$735K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$556K |
| 5 |
ARM
Adirondack Research & Management
Guilderland,
New York
|
-$189K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Russell Investments Group
London,
United Kingdom
| – | -$735K | -2,651 | Closed |
|
|
WPC
27
White Pine Capital
Bloomington,
Minnesota
| – | -$92K | -370 | Closed |
|
|
RC
28
RBF Capital
San Francisco,
California
| – | -$25K | -99 | Closed |
|
29
Two Sigma Investments
New York
| – | -$17K | -68 | Closed |
|
|
AG
30
Aperio Group
Sausalito,
California
| – | -$5K | -22 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$2.35K | -9 | -90% |
|
|
CIAS
32
Capital Investment Advisory Services
Raleigh,
North Carolina
| – | -$2K | -7 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -4 | Closed |
|
34
UBS Group
Zurich,
Switzerland
| – | -$1K | -3 | Closed |
|
35
Simplex Trading
Chicago,
Illinois
| – | +$782 | +3 | New |
|
TRIB Hedge Fund Activity: Q3 2019 in Review
28 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2019, worth a combined $12.9M — down 36% from $20.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TRIB and 3 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 3 added.
The largest buyer was Stonehill Capital Management, adding an estimated $959K. The largest seller was Lapides Asset Management, exiting entirely with an estimated $1.08M sold.
- 28 institutional investors held Trinity Biotech (TRIB) as of Q3 2019, down from 34 in Q2 2019.
- Funds reported $12.9M of Trinity Biotech stock for Q3 2019, down 36% quarter-over-quarter.
- 3 funds opened new Trinity Biotech positions in Q3 2019 and 9 closed out, a net change of -6 holders.
- The largest Trinity Biotech buyer in Q3 2019 was Stonehill Capital Management, an estimated $959K added.
- The largest Trinity Biotech seller in Q3 2019 was Lapides Asset Management, an estimated $1.08M sold.
Based on aggregated 13F filings for Q3 2019.